Basic Information
Stribild
Regulatory Information
EMEA/H/C/002574
May 24, 2013
26
July 23, 2024
Company Information
Ireland
IDA Business & Technology Park Carrigtohill County Cork T45 DP77
GILEAD SCIENCES IRELAND UC
Active Substances Detail
elvitegravircobicistatemtricitabinetenofovir disoproxil fumarate
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Stribild. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Stribild. For practical information about using Stribild, patients should read the package leaflet or contact their doctor or pharmacist.